A Phase 2 interventional study of Abatacept (BMS-188667) and Abatacept (BMS-188667) in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 57 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-01.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is one of 2 that started in 2000, is one of 9 in phase 2, and was the 8th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 2 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 524 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2000, is one of 10 in phase 2, and was the 8th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.
All participants who completed the 12-month double-blind study period were eligible to continue in the open-label study. Participants received placebo, Abatacept 2 mg/kg, or Abatacept 10 mg/kg in the double-blind study. Participants receiving placebo in the double-blind study were switched 1:1 to continued treatment with placebo or Abatacept 2 mg/kg. Participants receiving Abatacept 2 mg/kg or Abatacept 10 mg/kg continued at the double-blind study dosage. After results from the double-blind period became available, all participants were switched to a weight-tiered 10 mg/kg dose of Abatacept.
Open label study design: Single group assignment, Single arm, Open label,
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Double blind study phase:
Washout/drug stabilization requirements (except Methotrexate) [ must be signed before making any changes in RA therapy if those changes are solely for the purpose of this study].
Eligibility of subjects for the study is based on their disease activity and anti-rheumatic treatment at the initial visit:
At entry, Methotrexate monotherapy must have a disease activity:
At entry, combination therapy must have a disease activity (if subject does not satisfy the above):
In addition
All subjects who were on combination therapy at entry must undergo a 28 day of DMARDs other than Methotrexate. After the washout/drug stabilization and prior to randomization such subjects must have:
Open label study phase:
Exclusion Criteria:
Double blind study phase:
Subjects with the following laboratory values:
Open label study phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abatacept (BMS-188667)
Drug: Abatacept (BMS-188667)
Drug: Abatacept (BMS-188667)
Drug: Placebo
IV, 10 mg/Kg, monthly, for the duration of the trial
Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.
Time frame: Day 180
Participants Receiving Concomitant Disease Modifying Rheumatic Drugs and Biologics in Open-Label (OL) Period
The number of participants receiving concomitant rheumatoid arthritis treatment with disease modifying rheumatic drugs and/or biologics.
Time frame: Day 360 to Day 3,060
Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) in OL Period
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related AE/SAE=Certain,Probable,Possible,or Missing relationship to drug.
Time frame: Day 360 to Day 3060
Number of Participants With AEs of Special Interest in OL Period
AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest were those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion. Peri-Infusional AEs were defined as those that occurred within 24 hours after the start of the infusion.
Time frame: Day 360 to Day 3060
Baseline Serum Immunoglobulin A (IgA) Over Time in OL Period
Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 6.
Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, and 1800
Mean Change From Baseline (BL) in IgA Over Time in OL Period
Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgA. Baseline data for these time-matched cohorts are presented in Outcome Measure 5.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Baseline Immunoglobulin G (IgG) Over Time in OL Period
Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 8.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440 and 1800
Mean Change From Baseline (BL) in IgG Over Time in OL Period
Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgG. Baseline data for these cohorts are presented in Outcome Measure 7.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Baseline Immunoglobulin M (IgM) Over Time in OL Period
Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 10.
Time frame: Baseline (Day 0) and Days 360, 720,1080,1440, and 1800
Mean Change From Baseline (BL) in IgM in OL Period
Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgM. Baseline data for these time-matched cohorts are presented in Outcome Measure 9.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Number of Participants With Hematology Values Meeting Marked Abnormality Criteria in OL Period
Time frame: Day 360 to Day 3060
Number of Participants With Liver and Kidney Function Values Meeting Marked Abnormality Criteria in OL Period
Time frame: Day 360 to Day 3060
Number of Participants With Electrolyte Values Meeting Marked Abnormality Criteria in OL Period
Time frame: Day 360 to Day 3060
Number of Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting Marked Abnormality Criteria in OL Period
Time frame: Day 360 to Day 3060
Number of ACR 20 Responders in DB Period
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.
Time frame: Days 15, 30, 60, 90, 120, 150,180, 240, 300, and 360
Number of ACR 50 Responders in DB Period
ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.
Time frame: Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
Number of ACR 70 Responders in DB Period
ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.
Time frame: Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
ACR Numeric Values (ACR-N)
The ACR-N is calculated for each participant by taking the lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening.
Time frame: Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
ACR-N Area Under The Curve (AUC) on Day 180 and Day 360
The AUC for ACR-N is the measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute the AUC. The ACR-N AUC was compared between the two abatacept treatment groups and the placebo group using an analysis of variance (ANOVA) for 6- and 12-month data (Day 180 and Day 360). This allowed for the assessment of subject response throughout the study. See Measure Description in Outcome Measure 18 for a definition of ACR-N.
Time frame: Baseline and Day 180; Baseline and Day 360
Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 180
Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])
Time frame: Baseline, Day 180
Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 360
Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])
Time frame: Baseline, Day 360
Mean Changes From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Day 180 and Day 360
SF-36 measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS=physical functioning, role-physical, bodily pain, and general health; MCS=vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0=worst score (or quality of life) and 100=best score.
Time frame: Baseline, Day 180, Day 360
Adjusted Mean Percent Changes From Baseline in the Modified Health Assessment Questionnaire (mHAQ) at Day 180 and Day 360
A shortened version of the Health Assessment Questionnaire (HAQ), which uses only 8 instead of the 20 original items and is used to assess motor performance in everyday activities, such as dressing, turning a faucet on/off, and getting in and out of a car. Percent change from baseline = (baseline - post baseline value) / baseline value x 100.
Time frame: Baseline, Day 180, Day 360
Number of Participants With At Least One New Active Joint (Tender Joints and Swollen Joints) at Day 180 and Day 360
Time frame: Day 180, Day 360
Participants Who Experienced Death, Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations During the Double-Blind Period
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Related events include those that were considered by the investigator to be certain, probable, or possibly related to study drug.
Time frame: From the start of study through the end of the double-blind period (at 12 months)
Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Blood Chemistry Values During Double-Blind Therapy
Time frame: From the start of study up to 60 days post the end of the 12-month double-blind period
Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Hematologic Values During Double-Blind Therapy
Time frame: From the start of study up to 60 days post the end of the 12-month double-blind period
Number of Participants Who Discontinued Due to Lack of Efficacy in the DB and OL Periods
Time frame: Day 1 to Day 360 (Double-Blind Period), Day 361 to Day 3060 (Open-Label Period)
Immunogenicity Data: Anti-CTLA4Ig Antibodies With Immunoglobulin (IG) Region
Time frame: Baseline, Days 30, 90, 180, 270, 360
Immunogenicity Data: Anti-CTLA4Ig Antibodies Without IG Region
Time frame: Baseline, Days 30, 90, 180, 270, 360
Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion (Anti-CTLA4Ig Antibodies With IG Region)
Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.
Time frame: Baseline, Days 30, 90, 180, 270, 360
Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion(Anti-CTLA4Ig Antibodies Without IG Region)
Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.
Time frame: Baseline, Days 30, 90, 180, 270, 360
Pharmacodynamic Measure: Mean Changes From Baseline in Rheumatoid Factor at Day 180 and Day 360
Time frame: Baseline, Day 180, Day 360
Pharmacodynamic Measure: Mean Changes From Baseline in Interleukin-6 at Day 180 and Day 360
Time frame: Baseline, Day 180, Day 360
Pharmacodynamic Measure: Mean Changes From Baseline in Plasma Soluble Interleukin-2 Receptor (sIL-2R) at Day 180 and Day 360
Time frame: Baseline, Day 180, Day 360
Pharmacodynamic Measure: Mean Changes From Baseline in E-Selectin at Day 180 and Day 360
Time frame: Baseline, Day 180, Day 360
Pharmacodynamic Measure: Mean Changes From Baseline in Soluble Inter-Cellular Adhesion Molecule 1 (sICAM-1) at Day 180 and Day 360
Time frame: Baseline, Day 180, Day 360
Pharmacodynamic Measure: Mean Changes From Baseline in Tumor Necrosis Factor (TNF)-Alpha at Day 180 and Day 360
Time frame: Baseline, Day 180, Day 360
Number of ACR 20 Responders in OL Period
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.
Time frame: Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Number of ACR 50 Responders in the OL Period
ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.
Time frame: Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Number of ACR 70 Responders in the OL Period
ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in 3 of the following 5 parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.
Time frame: Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Number of Participants With a Clinically Meaningful Improvement on the Modified Health Assessment Questionnaire (mHAQ) in OL Period
The mHAQ is a self-administered questionnaire composed of 20 questions that assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The answers are graded on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The HAQ disease index is a weighted sum of the scale scores, with a higher score indicating poorer function. A clinically meaningful improvement was defined as a reduction from baseline in mHAQ score of at least 0.30 units.
Time frame: Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Baseline Level of Serum Rheumatoid Factor Over Time in OL Period
Serum evaluations were carried out to determine participant baseline rheumatoid factor serum concentration. Time-matched baseline(Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.
Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline in Serum Rheumatoid Factor Level Over Time in OL Period
Serum evaluations were carried out to determine participant change from baseline in rheumatoid factor serum concentration. Mean change from baseline = value at post-baseline OL time point-value and baseline OL time point.
Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Baseline Soluble Serum Interleukin-2 Receptor Level (sIL2-r) Over Time in OL Period
Serum evaluations were carried out to determine participant serum levels of sIL2-r at baseline. Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.
Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline in sIL2-r Over Time in OL Period
Serum evaluations were carried out to determine participant serum levels of sIL2-r. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Mean Baseline Serum C-Reactive Protein Level Over Time in OL Period
Serum evaluations were carried out to evaluate participant serum CRP concentrations at baseline. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.
Time frame: Baseline (Day 0) and Days 360, 720, 1080,1440,1800, 2160, 2520, 2880, 3060
Mean Change From Baseline in Level of C Reactive Protein Over Time in OL Period
Serum evaluations were carried out to evaluate participant concentrations of serum C reactive protein. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, 3060
Mean Baseline Physical Component Summary (PCS) of the Short-Form 36 (SF-36) Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 50.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Mean Change From Baseline (BL) in the Physical Component Summary (PCS) of the SF-36 Over Time in OL Period
The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 49.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Mean Baseline Mental Component Summary (MCS) of the SF-36 Over Time in OL Period
SF-36=PCS, MCS, \& 8 individual indices. MCS addresses 4 of the 8 indices: vitality, social functioning, role-emotional, \& mental health. Subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched baseline (Day 0) values \& post-baseline (BL) values are presented for each post-BL visit \& represent only that cohort with measurements available at that post-BL assessment. See Outcome Measure 51 for Change from BL.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Mean Change From Baseline (BL) in the MCS of the SF-36 Over Time in OL Period
The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 51.
Time frame: Baseline (Day 0) and Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Mean Baseline (BL) Physical Functioning Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 54.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline (BL) in the Physical Functioning Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 53.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Baseline Role-Physical Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 56.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline (BL) in the Role-Physical Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 55.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Baseline Bodily Pain Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 58.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From BL in the Bodily Pain Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 57.
Time frame: BL (Day 0); Day 360; Day 720; Day 1,080; Day 1,440; Day 1,800; Day 2,160; Day 2,520; Day 2,880; Day 3,060
Mean BL General Health Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 60.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline (BL) in the General Health Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 59.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Baseline Vitality Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 62.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline (BL) in the Vitality Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 61.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Baseline Social Functioning Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 64.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline (BL) in the Social Functioning Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 63.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Baseline Role-Emotional Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 66.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline (BL) in the Role-Emotional Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 65.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Baseline Mental Health Domain of the SF-36 Over Time in OL Period
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 68.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Mean Change From Baseline (BL) in the Mental Health Domain of the SF-36 Over Time in OL Period
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 67.
Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
| Milestone | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Open-Label (OL) Abatacept (10 mg / kg) |
|---|---|---|---|---|
| Started | 115 | 105 | 119 | 0 |
| Completed day 1 to day 181 | 98 | 80 | 78 | 0 |
| Completed | 90 | 74 | 71 | 0 |
| Not completed | 25 | 31 | 48 | 0 |
| Withdrew: Adverse event | 5 | 9 | 11 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 |
| Withdrew: Other reason | 1 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 13 | 17 | 30 | 0 |
| Withdrew: Withdrawal by subject | 5 | 2 | 6 | 0 |
| Milestone | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Open-Label (OL) Abatacept (10 mg / kg) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 219 |
| Completed | 0 | 0 | 0 | 82 |
| Not completed | 0 | 0 | 0 | 137 |
| Withdrew: Death | 0 | 0 | 0 | 7 |
| Withdrew: Adverse event | 0 | 0 | 0 | 46 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 26 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 31 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 9 |
| Withdrew: Other reasons | 0 | 0 | 0 | 15 |
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.
| Participants | DB Abatacept 10 mg/kg + Methotrexate | DB Abatacept 2 mg/kg + Methotrexate | DB Placebo + Methotrexate |
|---|---|---|---|
| Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period | 70 | 44 | 42 |
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.
| Participants | DB Abatacept 10 mg/kg + Methotrexate | DB Abatacept 2 mg/kg + Methotrexate | DB Placebo + Methotrexate |
|---|---|---|---|
| Day 15 | 30 | 9 | 24 |
| Day 30 | 48 | 22 | 36 |
| Day 60 | 65 | 35 | 41 |
| Day 90 | 62 | 40 | 42 |
| Day 120 | 71 | 47 | 45 |
| Day 150 | 67 | 46 | 42 |
| Day 180 | 70 | 44 | 42 |
| Day 240 | 72 | 43 | 42 |
| Day 300 | 73 | 41 | 41 |
| Day 360 | 72 | 44 | 43 |
ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.
| Participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Day 15 | 2 | 0 | 3 |
| Day 30 | 16 | 4 | 7 |
| Day 60 | 25 | 14 | 18 |
| Day 90 | 28 | 18 | 15 |
| Day 120 | 38 | 18 | 18 |
| Day 150 | 42 | 18 | 19 |
| Day 180 | 42 | 24 | 14 |
| Day 240 | 41 | 22 | 24 |
| Day 300 | 45 | 23 | 18 |
| Day 360 | 48 | 24 | 24 |
ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.
| Participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Day 15 | 0 | 0 | 0 |
| Day 30 | 4 | 3 | 0 |
| Day 60 | 10 | 4 | 0 |
| Day 90 | 10 | 5 | 1 |
| Day 120 | 15 | 6 | 4 |
| Day 150 | 16 | 6 | 4 |
| Day 180 | 19 | 11 | 2 |
| Day 240 | 21 | 9 | 6 |
| Day 300 | 27 | 11 | 3 |
| Day 360 | 24 | 13 | 9 |
The ACR-N is calculated for each participant by taking the lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening.
| units on a scale | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Day 15 (n=113, 104, 118) | 11.09 ± 15.53 | 5.26 ± 10.37 | 9.07 ± 14.76 |
| Day 30 (n=115, 104, 117) | 20.45 ± 23.41 | 12.06 ± 18.11 | 13.20 ± 17.85 |
| Day 60 (n=114, 105, 119) | 28.85 ± 26.78 | 17.69 ± 22.83 | 17.09 ± 20.90 |
| Day 90 (n=115, 105, 118) | 29.03 ± 27.38 | 21.12 ± 26.10 | 16.93 ± 21.61 |
| Day 120 (n=114, 105, 115) | 33.80 ± 29.35 | 22.87 ± 26.10 | 19.26 ± 23.70 |
| Day 150 (n=114, 103, 118) | 36.34 ± 30.29 | 22.69 ± 24.15 | 19.37 ± 24.74 |
| Day 180 (n=114, 104, 118) | 37.65 ± 30.39 | 24.67 ± 29.03 | 17.29 ± 22.02 |
| Day 240 (n=115, 104, 119) | 38.34 ± 31.49 | 23.49 ± 27.51 | 20.71 ± 25.97 |
| Day 300 (n=114, 105, 119) | 39.69 ± 31.08 | 21.82 ± 27.99 | 18.69 ± 23.53 |
| Day 360 (n=115, 105, 119) | 40.87 ± 31.69 | 24.55 ± 29.37 | 20.49 ± 26.14 |
The AUC for ACR-N is the measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute the AUC. The ACR-N AUC was compared between the two abatacept treatment groups and the placebo group using an analysis of variance (ANOVA) for 6- and 12-month data (Day 180 and Day 360). This allowed for the assessment of subject response throughout the study. See Measure Description in Outcome Measure 18 for a definition of ACR-N.
| percentage*days | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Day 180 | 5021.70 ± 317.9 | 3242.54 ± 332.7 | 2889.07 ± 312.5 |
| Day 360 | 12035.1 ± 711.7 | 7447.87 ± 744.8 | 6393.49 ± 699.6 |
Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])
| percentage change | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Tender Joints (n=114, 104, 118) | 59.8 ± 3.6 | 43.2 ± 4.1 | 31.9 ± 5.0 |
| Swollen Joints (n=114, 104, 118) | 55.3 ± 3.5 | 45.3 ± 4.1 | 33.5 ± 4.3 |
| Pain (n=109, 102, 118) | 46.2 ± 4.1 | 22.1 ± 5.8 | 8.2 ± 7.0 |
| SAPF (n=107, 98, 110) | 41.2 ± 4.6 | 21.6 ± 6.5 | 13.7 ± 5.5 |
| Subject Global Assessment (n=111, 103, 118) | 40.8 ± 4.7 | 9.1 ± 10.4 | 17.5 ± 4.1 |
| Physician Global Assessment (n=111, 103, 116) | 51.9 ± 3.4 | 38.7 ± 4.4 | 25.1 ± 3.5 |
| C-Reactive Protein (n=108, 98, 114) | 31.8 ± 6.3 | 16.4 ± 7.0 | -23.4 ± 11.0 |
Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])
| percentage change | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Tender Joints (n=114, 104, 118) | 66.4 ± 3.8 | 43.6 ± 4.3 | 30.0 ± 5.3 |
| Swollen Joints (n=114, 104, 118) | 59.7 ± 3.7 | 46.4 ± 4.5 | 36.2 ± 4.4 |
| Pain (n=109, 102, 118) | 44.9 ± 4.7 | 26.2 ± 5.9 | 65.2 ± 12.6 |
| SAPF (n=107, 98, 110) | 42.3 ± 4.3 | 22.9 ± 5.0 | 10.3 ± 5.9 |
| Subject Global Assessment (n=111, 103, 118) | 41.0 ± 5.1 | 16.0 ± 8.9 | 2.0 ± 19.1 |
| Physician Global Assessment (n=111, 103, 116) | 53.5 ± 3.4 | 37.9 ± 4.2 | 24.1 ± 3.8 |
| C-Reactive Protein (n=108, 98, 114) | 27.6 ± 9.9 | 11.0 ± 9.5 | -31.3 ± 12.6 |
SF-36 measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS=physical functioning, role-physical, bodily pain, and general health; MCS=vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0=worst score (or quality of life) and 100=best score.
| units on a scale | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| PCS, Mean Change at Day 180 (n=115, 104, 119) | 8.3 ± 0.9 | 4.6 ± 0.7 | 3.0 ± 0.6 |
| MCS, Mean Change at Day 180 (n=115, 104, 119) | 5.0 ± 1.0 | 2.7 ± 1.2 | 3.2 ± 1.0 |
| PCS, Mean Change at Day 360 (n=115, 104, 119) | 8.1 ± 0.9 | 5.3 ± 0.8 | 2.8 ± 0.7 |
| PCS, Mean Change at Day 360 (n=115, 104, 119) | 5.7 ± 1.0 | 3.5 ± 1.1 | 3.0 ± 0.9 |
A shortened version of the Health Assessment Questionnaire (HAQ), which uses only 8 instead of the 20 original items and is used to assess motor performance in everyday activities, such as dressing, turning a faucet on/off, and getting in and out of a car. Percent change from baseline = (baseline - post baseline value) / baseline value x 100.
| Percentage of Change on mHAQ scale | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Mean Percentage Change at Day 180 (n=107, 98, 110) | 41.39 ± 5.43 | 21.41 ± 5.67 | 13.73 ± 5.35 |
| Mean PercentageChange at Day 360 (n=109, 100, 111) | 42.49 ± 5.05 | 22.74 ± 5.27 | 10.26 ± 5.00 |
| participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| New Tender Joints(s) at Day 180 | 47 | 65 | 70 |
| New Swollen Joints(s) at Day 180 | 55 | 59 | 75 |
| New Tender Joints(s) at Day 360 | 33 | 62 | 69 |
| New Swollen Joints(s) at Day 360 | 45 | 59 | 69 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Related events include those that were considered by the investigator to be certain, probable, or possibly related to study drug.
| Participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Deaths | 0 | 1 | 0 |
| SAEs | 14 | 19 | 19 |
| Discontinuations due to SAEs | 3 | 6 | 3 |
| Related SAEs | 2 | 5 | 2 |
| Discontinuations due to AEs | 6 | 10 | 11 |
| AEs | 104 | 104 | 112 |
| Related AEs | 56 | 50 | 58 |
| Participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| High Alanine Aminotransferase (ALT) | 0 | 1 | 2 |
| High Aspartate Aminotransferase (AST) | 0 | 1 | 0 |
| High Creatinine | 4 | 3 | 4 |
| Low Potassium | 2 | 3 | 1 |
| High Potassium | 1 | 3 | 4 |
The number of participants receiving concomitant rheumatoid arthritis treatment with disease modifying rheumatic drugs and/or biologics.
| Participants | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Methotrexate | 84 | 68 | 67 |
| Corticosteroids (oral and/or injectable) | 72 | 57 | 56 |
| Nonsteroidal antiinfllammatory drugs | 78 | 63 | 64 |
| Azanthioprine | 1 | 0 | 1 |
| Chloroquine | 0 | 1 | 1 |
| Cyclosporine | 2 | 1 | 0 |
| Gold Sodium Thiomalate | 0 | 1 | 0 |
| Hydroxychloroquine | 2 | 3 | 2 |
| Leflunamide | 2 | 0 | 1 |
| Sulfasalazine | 0 | 0 | 1 |
| Adalimumab | 0 | 1 | 0 |
| Etanercept | 0 | 1 | 0 |
| Infliximab | 2 | 1 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related AE/SAE=Certain,Probable,Possible,or Missing relationship to drug.
| Participants | OL Abatacept (10 mg / kg) |
|---|---|
| AEs | 211 |
| Related AEs | 144 |
| Discontinued Due to AEs | 44 |
| SAEs | 117 |
| Related SAEs | 37 |
| Discontinued Due to SAEs | 33 |
| Deaths | 8 |
AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest were those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion. Peri-Infusional AEs were defined as those that occurred within 24 hours after the start of the infusion.
| Participants | OL Abatacept (10 mg / kg) |
|---|---|
| Infections/Infestations | 179 |
| Malignant Neoplasms | 20 |
| Autoimmune Disorders | 20 |
| Acute Infusional AEs | 20 |
| Peri-Infusional AEs | 47 |
Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 6.
| mg/dL | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Baseline for Day 360 cohort (n=74, 59, 60) | 308.09 ± 152.27 | 341.54 ± 148.48 | 264.22 ± 133.90 |
| Baseline for Day 720 cohort (n=71, 53, 53) | 290.25 ± 146.27 | 338.58 ± 151.76 | 256.64 ± 132.78 |
| Baseline for Day 1080 cohort (n=59, 45, 45) | 287.27 ± 140.22 | 321.02 ± 153.81 | 266.89 ± 143.48 |
| Baseline for Day 1440 cohort (n=54, 37, 37) | 287.09 ± 136.50 | 327.27 ± 162.13 | 250.11 ± 127.88 |
| Baseline for Day 1800 cohort (n=50, 38, 34) | 292.78 ± 146.91 | 327.34 ± 163.27 | 244.71 ± 118.03 |
Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgA. Baseline data for these time-matched cohorts are presented in Outcome Measure 5.
| mg/dL | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Change from BL at Day 360 (n=74, 59, 60) | -38.24 ± 5.95 | -25.66 ± 7.83 | 5.00 ± 6.72 |
| Change from BL at Day 720 (n=71, 53, 53) | -28.20 ± 8.61 | -45.06 ± 9.27 | -20.89 ± 7.73 |
| Change from BL at Day 1080 (n=59, 45, 45) | -33.10 ± 13.08 | -52.87 ± 12.86 | -15.87 ± 11.18 |
| Change from BL at Day 1440 (n=54, 37, 37) | -30.52 ± 9.75 | -52.49 ± 16.32 | -4.41 ± 12.28 |
| Change from BL at Day 1800 (n=50, 38, 34) | -20.06 ± 26.97 | -65.95 ± 16.26 | -25.68 ± 12.18 |
| Participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Low Hemoglobin (n=115, 104, 119) | 1 | 0 | 3 |
| Low Platelets (n=114, 104, 119) | 0 | 0 | 0 |
| High Platelets (n=114, 104, 119) | 0 | 0 | 0 |
| Low Leukocytes (n=115, 104, 119) | 0 | 0 | 0 |
| High Leukocytes (n=115, 104, 119) | 12 | 6 | 14 |
| Low Neutrophils (n=115, 105, 119) | 0 | 1 | 0 |
| participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Open-Label (OL) Abatacept (10 mg / kg) |
|---|---|---|---|---|
| Number of Participants Who Discontinued Due to Lack of Efficacy in the DB and OL Periods | 12 | 16 | 28 | 26 |
| titers | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate |
|---|---|---|
| Baseline for Day 30 Cohort (n=110, 100) | 9151.8 ± 10692.68 | 8861.8 ± 9282.06 |
| Day 30 (n=110, 100) | 8361.5 ± 9931.79 | 8561.7 ± 9323.91 |
| Baseline for Day 90 Cohort (n=110, 99) | 9052.8 ± 10392.26 | 8930.2 ± 9002.57 |
| Day 90 (n=110, 99) | 6842.3 ± 7659.01 | 7497.8 ± 7356.42 |
| Baseline for Day 180 Cohort (n=102, 90) | 8853.6 ± 10330.92 | 8689.3 ± 8626.90 |
| Day 180 (n=102, 90) | 5967.3 ± 6535.57 | 7016.5 ± 6945.59 |
| Baseline for Day 270 Cohort (n=94, 73) | 13149.7 ± 14850.07 | 11976.7 ± 13679.48 |
| Day 270 (n=94, 73) | 8027.5 ± 8863.47 | 9725.9 ± 11337.20 |
| Baseline for Day 360 Cohort (n=83, 74) | 13287.8 ± 15024.78 | 11712.4 ± 12971.16 |
| Day 360 (n=83, 74) | 8675.1 ± 10038.76 | 10284.1 ± 12175.48 |
| titers | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate |
|---|---|---|
| Baseline for Day 30 Cohort (n=110, 101) | 12.6 ± 9.59 | 11.7 ± 4.79 |
| Day 30 (n=110, 101) | 12.5 ± 9.38 | 12.0 ± 5.58 |
| Baseline for Day 90 Cohort (n=110, 99) | 12.5 ± 9.42 | 11.6 ± 4.69 |
| Day 90 (n=110, 99) | 12.0 ± 8.31 | 11.4 ± 3.96 |
| Baseline for Day 180 Cohort (n=102, 90) | 12.6 ± 9.91 | 11.6 ± 4.76 |
| Day 180 (n=102, 90) | 12.1 ± 8.66 | 11.7 ± 5.01 |
| Baseline for Day 270 Cohort (n=95, 73) | 13.4 ± 10.51 | 12.1 ± 5.22 |
| Day 270 (n=95, 73) | 12.5 ± 8.70 | 11.7 ± 4.42 |
| Baseline for Day 360 Cohort (n=84, 76) | 13.6 ± 11.03 | 12.2 ± 5.77 |
| Day 360 (n=84, 76) | 12.9 ± 9.79 | 11.6 ± 4.42 |
Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.
| participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate |
|---|---|---|
| Day 30, ratio <=3 (n=110, 100) | 109 | 100 |
| Day 30, ratio <3 to <=9 (n=110, 100) | 1 | 0 |
| Day 30, ratio >9 (n=110, 100) | 0 | 0 |
| Day 90, ratio <=3 (n=110, 99) | 110 | 99 |
| Day 90, ratio <3 to <=9 (n=110, 99) | 0 | 0 |
| Day 90, ratio >9 (n=110, 99) | 0 | 0 |
| Day 180, ratio <=3 (n=102, 90) | 101 | 90 |
| Day 180, ratio <3 to <=9 (n=102, 90) | 1 | 0 |
| Day 180, ratio >9 (n=102, 90) | 0 | 0 |
| Day 270, ratio <=3 (n=94, 73) | 94 | 73 |
| Day 270, ratio <3 to <=9 (n=94, 73) | 0 | 0 |
| Day 270, ratio >9 (n=94, 73) | 0 | 0 |
| Day 360, ratio <=3 (n=83, 74) | 81 | 72 |
| Day 360, ratio <3 to <=9 (n=83, 74) | 2 | 2 |
| Day 360, ratio >9 (n=83, 74) | 0 | 0 |
Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 8.
| mg/dL | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Baseline for Day 360 cohort (n=75, 59, 60) | 1130.31 ± 295.28 | 1086.05 ± 263.41 | 1079.00 ± 345.72 |
| Baseline for Day 720 cohort (n=72, 53, 53) | 1138.58 ± 303.24 | 1093.23 ± 318.24 | 1076.40 ± 333.08 |
| Baseline for Day 1080 cohort (n=60, 45, 45) | 1145.15 ± 305.51 | 1053.91 ± 264.53 | 1136.27 ± 372.58 |
| Baseline for Day 1440 cohort (n=55, 37, 37) | 1154.58 ± 315.00 | 1095.49 ± 261.86 | 1135.43 ± 381.72 |
| Baseline for Day 1800 cohort (n=51, 38, 34) | 1152.63 ± 305.01 | 1092.76 ± 260.85 | 1137.21 ± 368.39 |
Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgG. Baseline data for these cohorts are presented in Outcome Measure 7.
| mg/dL | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Change from BL at Day 360 (n=75, 59, 60) | -181.92 ± 19.78 | -110.71 ± 21.46 | -15.12 ± 21.71 |
| Change from BL at Day 720 (n=72, 53, 53) | -183.04 ± 28.58 | -168.55 ± 31.82 | -137.06 ± 31.62 |
| Change from BL at Day 1080 (n=60, 45, 45) | -199.58 ± 33.68 | -229.91 ± 26.75 | -150.40 ± 33.97 |
| Change from BL at Day 1440 (n=55, 37, 37) | -228.11 ± 28.90 | -279.14 ± 33.43 | -147.46 ± 45.84 |
| Change from BL at Day 1800 (n=51, 38, 34) | -217.43 ± 39.52 | -206.21 ± 39.10 | -187.94 ± 44.40 |
Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 10.
| mg/dL | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Baseline for Day 360 cohort (n=74, 59, 60) | 147.76 ± 76.05 | 134.29 ± 66.81 | 125.10 ± 52.12 |
| Baseline for Day 720 cohort (n=71, 53, 53) | 147.76 ± 76.31 | 137.79 ± 69.93 | 123.25 ± 52.79 |
| Baseline for Day 1080 cohort (n=59, 45, 45) | 144.75 ± 78.89 | 127.36 ± 68.06 | 129.04 ± 54.79 |
| Baseline for Day 1440 cohort (n=54, 37, 37) | 141.69 ± 77.90 | 136.22 ± 70.90 | 133.51 ± 58.04 |
| Baseline for Day 1800 cohort (n=45, 33, 32) | 133.22 ± 61.79 | 124.15 ± 67.07 | 124.63 ± 58.69 |
Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.
| participants | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate |
|---|---|---|
| Day 30, ratio <=3 (n=110, 101) | 108 | 99 |
| Day 30, ratio <3 to <=9 (n=110, 101) | 1 | 2 |
| Day 30, ratio >9 (n=110, 101) | 1 | 0 |
| Day 90, ratio <=3 (n=110, 99) | 110 | 99 |
| Day 90, ratio <3 to <=9 (n=110, 99) | 0 | 0 |
| Day 90, ratio >9 (n=110, 99) | 0 | 0 |
| Day 180, ratio <=3 (n=102, 90) | 101 | 89 |
| Day 180, ratio <3 to <=9 (n=102, 90) | 1 | 0 |
| Day 180, ratio >9 (n=102, 90) | 0 | 1 |
| Day 270, ratio <=3 (n=95, 73) | 95 | 73 |
| Day 270, ratio <3 to <=9 (n=95, 73) | 0 | 0 |
| Day 270, ratio >9 (n=95, 73) | 0 | 0 |
| Day 360, ratio <=3 (n=84, 76) | 84 | 76 |
| Day 360, ratio <3 to <=9 (n=84, 76) | 0 | 0 |
| Day 360, ratio >9 (n=84, 76) | 0 | 0 |
| IU/mL | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Mean Change at Day 180 (n=95, 84, 74) | -104.3 (-151.5 to 57.0) | -28.1 (-52.1 to -4.1) | -0.6 (-31.7 to 30.4) |
| Mean Change at Day 360 (n=69, 54, 57) | -118.3 (-175.2 to -61.4) | -23.6 (-56.8 to 9.7) | 20.9 (-11.3 to 53.1) |
| pg/mL | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Mean Change at Day 180 (n=85, 74, 68) | -20.5 (-27.8 to -13.2) | -16.1 (-24.2 to -8.0) | 1.3 (-7.9 to 10.5) |
| Mean Change at Day 360 (n=56, 47, 47) | -20.9 (-31.6 to -10.2) | -12.7 (-22.5 to -2.9) | -0.6 (-8.1 to 6.9) |
| pg/mL | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Mean Change at Day 180 (n=94, 84, 76) | -315.9 (-418.5 to -213.3) | -135.5 (-241.5 to -29.5) | 43.6 (-71.2 to 158.4) |
| Mean Change at Day 360 (n=68, 55, 54) | -194.3 (-305.7 to -83.0) | 40.4 (-71.5 to 152.3) | 196.8 (24.3 to 369.4) |
| ng/mL | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Mean Change at Day 180 (n=88, 80, 71) | -8.3 (-13.2 to -3.4) | 0.5 (-6.0 to 7.0) | -0.7 (-6.9 to 5.5) |
| Mean Change at Day 360 (n=75, 67, 61) | -10.9 (-15.7 to -6.1) | 0.6 (-6.0 to 9.0) | 2.0 (-4.9 to 9.0) |
| ng/mL | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Mean Change at Day 180 (n=94, 82, 75) | -40.6 (-58.5 to -22.8) | -6.2 (-27.5 to 15.1) | 1.1 (-31.9 to 34.1) |
| Mean Change at Day 360 (n=77, 67, 63) | -55.2 (-74.8 to -35.5) | -13.6 (-36.3 to 9.0) | 0.7 (-27.6 to 28.9) |
| ng/mL | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate |
|---|---|---|---|
| Mean Change at Day 180 (n=83, 74, 68) | -3.7 (-8.7 to 1.3) | -1.2 (-4.3 to 1.9) | -3.6 (-8.0 to 0.7) |
| Mean Change at Day 360 (n=61, 48, 49) | -3.0 (-8.7 to 2.7) | 1.1 (-1.3 to 3.4) | -0.3 (-3.2 to 2.7) |
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.
| Participants | OL Abatacept: Original 10 mg/kg Group | OL Abatacept: Original 2 mg/kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Day 360 (n=84, 68, 67) | 64 | 40 | 37 |
| Day 450 (n=83, 67, 66) | 56 | 45 | 46 |
| Day 540 (n=82, 65, 59) | 61 | 45 | 45 |
| Day 630 (n=79, 63, 59) | 60 | 44 | 44 |
| Day 720 (n=75, 59, 56) | 58 | 39 | 43 |
| Day 810 (n=73, 56, 54) | 49 | 41 | 44 |
| Day 900 (n=69, 53, 51) | 56 | 42 | 42 |
| Day 990 (n=66, 52, 51) | 52 | 39 | 40 |
| Day 1080 (n=66, 50, 49) | 48 | 39 | 35 |
| Day 1170 (n=65, 50, 49) | 46 | 35 | 36 |
| Day 1260 (n=64, 49, 46) | 48 | 41 | 39 |
| Day 1350 (n=62, 48, 44) | 46 | 30 | 37 |
| Day 440 (n=61, 47, 44) | 43 | 38 | 37 |
| Day 1530 (n=60, 46, 43) | 45 | 35 | 29 |
| Day 1620 (n=58, 45, 43) | 44 | 35 | 38 |
| Day 1710 (n=58, 45, 42) | 37 | 34 | 38 |
| Day 1800 (n=56, 44, 42) | 44 | 32 | 38 |
| Day 1980 (n=53, 44, 40) | 37 | 34 | 28 |
| Day 2160 (n=49, 42, 38) | 39 | 33 | 32 |
| Day 2340 (n=47, 36, 36) | 35 | 27 | 28 |
| Day 2520 (n=43, 37, 33) | 31 | 30 | 28 |
| Day 2700 (n=37, 34, 34) | 33 | 26 | 23 |
| Day 2880 (n=36, 31, 32) | 28 | 28 | 27 |
| Day 3060 (n=18, 18, 17) | 13 | 13 | 14 |
ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.
| Participants | OL Abatacept: Original 10 mg/kg Group | OL Abatacept: Original 2 mg/kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Day 360 (n=84, 68, 67) | 44 | 23 | 21 |
| Day 450 (n=83, 67, 66) | 41 | 30 | 30 |
| Day 540 (n=82, 65, 59) | 38 | 28 | 31 |
| Day 630 (n=79, 63, 59) | 38 | 27 | 31 |
| Day 720 (n=75, 59, 56) | 43 | 29 | 34 |
| Day 810 (n=73, 56, 54) | 42 | 23 | 30 |
| Day 900 (n=69, 53, 51) | 40 | 34 | 29 |
| Day 990 (n=66, 52, 51) | 40 | 28 | 31 |
| Day 1,080 (n=66, 50, 49) | 35 | 24 | 29 |
| Day 1,170 (n=65, 50, 49) | 36 | 27 | 29 |
| Day 1,260 (n=64, 49, 46) | 33 | 24 | 28 |
| Day 1,350 (n=62, 48, 44) | 28 | 24 | 28 |
| Day 1,440 (n=61, 47, 44) | 25 | 33 | 24 |
| Day 1,530 (n=60, 46, 43) | 33 | 28 | 26 |
| Day 1,620 (n=58, 45, 43) | 29 | 27 | 26 |
| Day 1,710 (n=58, 45, 42) | 23 | 27 | 25 |
| Day 1,800 (n=56, 44, 42) | 34 | 28 | 28 |
| Day 1,980 (n=53, 44, 40) | 31 | 26 | 22 |
| Day 2,160 (n=49, 42, 38) | 25 | 30 | 25 |
| Day 2,340 (n=47, 36, 36) | 24 | 15 | 21 |
| Day 2,520 (n=43, 37, 33) | 25 | 23 | 21 |
| Day 2,700 (n=37, 34, 34) | 23 | 19 | 17 |
| Day 2,880 (n=36, 31, 32) | 23 | 18 | 19 |
| Day 3,060 (n=18, 18, 17) | 8 | 10 | 9 |
ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in 3 of the following 5 parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.
| Participants | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Day 360 (n=84, 68, 67) | 24 | 13 | 9 |
| Day 450 (n=83, 67, 66) | 21 | 14 | 12 |
| Day 540 (n=82, 65, 59) | 28 | 15 | 12 |
| Day 630 (n=79, 63, 59) | 25 | 17 | 15 |
| Day 720 (n=75, 59, 56) | 22 | 18 | 16 |
| Day 810 (n=73, 56, 54) | 20 | 14 | 11 |
| Day 900 (n=69, 53, 51) | 19 | 16 | 15 |
| Day 990 (n=66, 52, 51) | 23 | 17 | 17 |
| Day 1080 (n=66, 50, 49) | 21 | 18 | 16 |
| Day 1170 (n=65, 50, 49) | 23 | 16 | 17 |
| Day 1260 (n=64, 49, 46) | 20 | 12 | 20 |
| Day 1350 (n=62, 48, 44) | 18 | 13 | 13 |
| Day 1440 (n=61, 47, 44) | 19 | 16 | 15 |
| Day 1530 (n=60, 46, 43) | 22 | 16 | 13 |
| Day 1620 (n=58, 45, 43) | 21 | 15 | 16 |
| Day 1710 (n=58, 45, 42) | 15 | 18 | 12 |
| Day 1800 (n=56, 44, 42) | 21 | 17 | 15 |
| Day 1980 (n=53, 44, 40) | 25 | 16 | 10 |
| Day 2160 (n=49, 42, 38) | 23 | 18 | 11 |
| Day 2340 (n=47, 36, 36) | 19 | 11 | 14 |
| Day 2520 (n=43, 37, 33) | 19 | 16 | 11 |
| Day 2700 (n=37, 34, 34) | 20 | 12 | 12 |
| Day 2880 (n=36, 31, 32) | 17 | 10 | 12 |
| Day 3060 (n=18, 18, 17) | 6 | 6 | 7 |
The mHAQ is a self-administered questionnaire composed of 20 questions that assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The answers are graded on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The HAQ disease index is a weighted sum of the scale scores, with a higher score indicating poorer function. A clinically meaningful improvement was defined as a reduction from baseline in mHAQ score of at least 0.30 units.
| Participants | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Day 360 (n=84, 68, 67) | 46 | 30 | 23 |
| Day 720 (n=75, 59, 56) | 39 | 34 | 21 |
| Day 1080 (n=66, 50, 49) | 34 | 28 | 28 |
| Day 1440 (n=61, 47, 44) | 31 | 26 | 20 |
| Day 1800 (n=56, 44, 42) | 29 | 27 | 20 |
| Day 2160 (n=49, 42, 38) | 26 | 24 | 15 |
| Day 2520 (n=43, 37, 33) | 23 | 21 | 17 |
| Day 2880 (n=36, 31, 32) | 18 | 21 | 14 |
| Day 3060 (n=18, 18, 17) | 8 | 8 | 5 |
Serum evaluations were carried out to determine participant baseline rheumatoid factor serum concentration. Time-matched baseline(Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.
| IU/mL | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=80, 62, 65) | 291.98 ± 374.41 | 219.24 ± 262.55 | 233.57 ± 299.75 |
| Baseline for Day 720 cohort (n=69, 57, 54) | 256.12 ± 361.74 | 217.21 ± 267.03 | 227.81 ± 308.53 |
| Baseline for Day 1080 cohort (n=64, 49, 47) | 233.95 ± 346.73 | 172.00 ± 204.63 | 203.94 ± 250.44 |
| Baseline for Day 1440 cohort (n=57, 41, 41) | 243.32 ± 363.86 | 165.39 ± 173.31 | 215.71 ± 258.60 |
| Baseline for Day 1800 cohort (n=51, 41, 40) | 165.39 ± 152.94 | 175.41 ± 206.37 | 205.33 ± 254.25 |
| Baseline for Day 2160 (n=43, 34, 30) | 185.74 ± 173.26 | 181.91 ± 216.48 | 194.17 ± 254.30 |
| Baseline for Day 2520 (n=23, 24, 22) | 175.13 ± 156.99 | 158.42 ± 210.74 | 269.55 ± 309.15 |
| Baseline for Day 2880 (n=15, 16, 13) | 159.93 ± 123.69 | 197.63 ± 251.82 | 366.38 ± 362.39 |
| Baseline for Day 3060 (n=7, 9, 5) | 214.29 ± 120.00 | 223.44 ± 316.59 | 232.60 ± 202.38 |
Serum evaluations were carried out to determine participant change from baseline in rheumatoid factor serum concentration. Mean change from baseline = value at post-baseline OL time point-value and baseline OL time point.
| IU/mL | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change at Day 360 (n=80, 62, 65) | -72.78 ± 39.69 | -21.71 ± 14.50 | 7.77 ± 21.05 |
| Change at Day 720 (n=69, 57, 54) | 37.51 ± 76.03 | -40.23 ± 23.05 | -48.37 ± 48.47 |
| Change at Day 1080 (n=64, 49, 47) | 8.53 ± 66.71 | -34.78 ± 24.22 | -0.04 ± 38.15 |
| Change at Day 1440 (n=57, 41, 41) | 43.81 ± 97.15 | -15.68 ± 32.26 | 1.54 ± 49.24 |
| Change at Day 1800 (n=51, 41, 40) | 30.29 ± 30.78 | 10.95 ± 41.17 | -49.83 ± 40.58 |
| Change at Day 2160 (n=43, 34, 30) | -8.44 ± 45.19 | -26.29 ± 35.06 | -65.50 ± 51.49 |
| Change at Day 2520 (n=23, 24, 22) | 87.61 ± 99.50 | -54.92 ± 41.93 | -50.05 ± 70.38 |
| Change at Day 2880 (n=15, 16, 13) | 28.47 ± 45.91 | -102.06 ± 64.62 | 46.54 ± 193.55 |
| Change at Day 3060 (n=7, 9, 5) | -45.14 ± 88.72 | -89.00 ± 109.53 | 118.40 ± 252.72 |
Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgM. Baseline data for these time-matched cohorts are presented in Outcome Measure 9.
| mg/dL | OL Abatacept: Original 10 mg/kg Group | OL Abatacept: Original 2 mg/kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Change from BL at Day 360 (n=74, 59, 60) | -5.81 ± 3.49 | 3.22 ± 4.36 | 11.17 ± 3.89 |
| Change from BL at Day 720 (n=71, 53, 53) | 12.68 ± 7.32 | 0.11 ± 4.76 | 6.45 ± 6.11 |
| Change from BL at Day 1080 (n=59, 45, 45) | 0.37 ± 6.69 | 1.93 ± 6.61 | 27.93 ± 11.62 |
| Change from BL at Day 1440 (n=54, 37, 37) | 2.52 ± 7.07 | 0.68 ± 8.99 | 14.46 ± 9.52 |
| Change from BL at Day 1,800 (n=45, 33, 32) | 7.84 ± 6.89 | 9.06 ± 7.55 | 6.72 ± 8.80 |
| Participants | OL Abatacept (10 mg / kg) |
|---|---|
| Low Hemoglobin (> 13.0 grams/dL; n=216) | 21 |
| Low Hematocrit (< 35%; n=216) | 11 |
| Low Platelet Count (<145*10^9 cells/L; n=214) | 1 |
| High Platelet Count (>400*10^9 cells/L; n=214) | 1 |
| Low Leukocytes (<3.60 *10^3 cells/µL; n=216) | 12 |
| High Leukocytes (>10.30*10^3 cells/µL; n=216) | 49 |
| Low Neutrophils + Bands (<2.0*10^3 c/uL; n=217) | 1 |
| Low Absolute Lymphocytes(<1.0*10^3cells/µL; n=217) | 48 |
| High Absolute Lymphocytes(>3.5*10^3cells/µL;n=217) | 0 |
| High Absolute Monocytes (>720*10^3cells/µL; n=217) | 0 |
| High Absolute Basophils(>0.2*10^3 cells/µL; n=217) | 1 |
| High Absolute Eosinophils(>0.4*10^3cells/µL;n=217) | 21 |
| Participants | OL Abatacept (10 mg / kg) |
|---|---|
| High Alkaline Phosphatase (>117 IU/L) | 1 |
| High Aspartate Aminotransferase (>38 IU/L) | 6 |
| High Alanine Aminotransferase (>30 IU/L) | 5 |
| High G-Glutamyl Transferase (>61 IU/L) | 20 |
| High Total Bilirubin (>1.1 mg/dL) | 0 |
| High Blood Urea Nitrogen (>21.3 mg/dL) | 14 |
| High Creatinine (>1.30 mg/dL) | 13 |
| Participants | OL Abatacept (10 mg / kg) |
|---|---|
| Low Serum Sodium (<135 mEq/L; n=217) | 4 |
| High Serum Sodium (>145 mEq/L; n=217) | 10 |
| Low Serum Potassium (<3.5 mEq/L; n=217) | 8 |
| High Serum Potassium (>5.0 mEq/L; n=217) | 10 |
| Low Serum Chloride (<97 mEq/L; n=217) | 8 |
| High Serum Chloride (>106 mEq/L; n=217) | 3 |
| Low Total Calcium (<8.6 mg/dL; n=217) | 0 |
| High Total Calcium (>10.2 mg/dL; n=217) | 3 |
| Low Inorganic Phosphorus (<2.7 mg/dL; n=217) | 5 |
| High Inorganic Phosphorus (> 4.5 mg/dL; n=217) | 11 |
Serum evaluations were carried out to determine participant serum levels of sIL2-r at baseline. Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.
| pg/mL | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg /kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=69, 57, 58) | 1424.86 ± 790.75 | 1365.40 ± 524.90 | 1480.93 ± 713.88 |
| Baseline for Day 720 cohort (n=66, 53, 49) | 1419.82 ± 721.00 | 1351.15 ± 497.64 | 1437.24 ± 730.73 |
| Baseline for Day 1080 cohort (n=57, 47, 44) | 1413.28 ± 760.39 | 1341.51 ± 520.06 | 1392.09 ± 678.85 |
| Baseline for Day 1440 cohort (n=47, 36, 31) | 1418.64 ± 806.85 | 1323.14 ± 538.82 | 1409.71 ± 687.86 |
| Baseline for Day 1800 cohort (n=27, 13, 17) | 1252.04 ± 572.14 | 1160.15 ± 444.37 | 1476.06 ± 590.14 |
| Participants | OL Abatacept (10 mg / kg) |
|---|---|
| Low Serum Glucose (< 70 mg/dL; n=217) | 33 |
| High Serum Glucose (> 110 mg/dL; n=217) | 30 |
| Low Fasting Serum Glucose (< 70 mg/dL; n=1) | 0 |
| High Fasting Serum Glucose (> 110 mg/dL; n=1) | 0 |
| Low Total Protein (< 6.2 grams/dL; n=217) | 12 |
| High Total Protein (>8.3 grams/dL; n=217) | 1 |
| Low Albumin (<3.5 grams/dL; n=217) | 7 |
| High Uric Acid (>7.6 mg/dL; n=217) | 2 |
| High Urine Protein (> trace; n=217) | 29 |
| High Urine Glucose (> trace; n=217) | 32 |
| High Urine Blood (> trace; n=217) | 47 |
| High Urine White Blood Cell Count (> trace; n=162) | 74 |
| High Urine Red Blood Cell Count (> trace; n=162) | 51 |
Serum evaluations were carried out to determine participant serum levels of sIL2-r. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.
| pg/mL | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change at Day 360 (n=69, 57, 58) | -200.62 ± 56.43 | 44.05 ± 60.80 | 207.40 ± 91.17 |
| Change at Day 720 (n=66, 53, 49) | -323.26 ± 83.71 | -209.19 ± 60.08 | -213.22 ± 83.64 |
| Change at Day 1080 (n=57, 47, 44) | -158.93 ± 96.60 | -44.98 ± 95.04 | -156.20 ± 69.04 |
| Change at Day 1440 (n=47, 36, 31) | -421.57 ± 98.79 | -392.08 ± 81.78 | -394.45 ± 123.99 |
| Change at Day 1800 (n=27, 13, 17) | -249.81 ± 123.30 | -84.77 ± 61.61 | -247.12 ± 128.65 |
Serum evaluations were carried out to evaluate participant serum CRP concentrations at baseline. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.
| mg/dL | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=78, 65, 65) | 2.90 ± 2.25 | 3.02 ± 2.36 | 2.61 ± 2.20 |
| Baseline for Day 720 cohort (n=68, 54, 53) | 2.64 ± 2.03 | 3.16 ± 2.60 | 2.60 ± 2.03 |
| Baseline for Day 1080 cohort (n=61, 50, 47) | 2.58 ± 1.99 | 3.06 ± 2.63 | 2.52 ± 2.06 |
| Baseline for Day 1440 cohort (n=56, 46, 41) | 2.65 ± 2.02 | 3.11 ± 2.71 | 2.62 ± 2.16 |
| Baseline for Day 1800 cohort (n=52, 41, 41) | 2.40 ± 1.73 | 3.10 ± 2.75 | 2.64 ± 2.15 |
| Baseline for Day 2160 cohort (n=43, 34, 33) | 2.34 ± 1.66 | 2.91 ± 2.77 | 2.80 ± 2.36 |
| Baseline for Day 2520 cohort (n=36, 35, 32) | 2.46 ± 1.70 | 3.02 ± 2.79 | 2.86 ± 2.35 |
| Baseline for Day 2880 cohort (n=27, 26, 27) | 2.14 ± 1.42 | 2.95 ± 3.00 | 3.08 ± 2.49 |
| Baseline for Day 3060 cohort (n=14, 10, 8) | 1.93 ± 1.12 | 2.99 ± 3.07 | 2.72 ± 1.30 |
Serum evaluations were carried out to evaluate participant concentrations of serum C reactive protein. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.
| mg/dL | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change at Day 360 (n=78, 65, 65) | -1.38 ± 0.29 | -1.13 ± 0.33 | -0.08 ± 0.38 |
| Change at Day 720 (n=68, 54, 53) | -1.46 ± 0.25 | -2.08 ± 0.38 | -1.26 ± 0.28 |
| Change at Day 1080 (n=61, 50, 47) | -0.96 ± 0.44 | -1.93 ± 0.38 | -1.20 ± 0.35 |
| Change at Day 1440 (n=56, 46, 41) | -1.56 ± 0.33 | -1.91 ± 0.37 | -1.21 ± 0.44 |
| Change at Day 1800 (n=52, 41, 41) | -1.53 ± 0.25 | -1.33 ± 0.83 | -1.72 ± 0.35 |
| Change at Day 2160 (n=43, 34, 33) | -1.33 ± 0.37 | -2.11 ± 0.46 | -2.04 ± 0.42 |
| Change at Day 2520 (n=36, 35, 32) | -1.45 ± 0.39 | -2.29 ± 0.48 | -2.01 ± 0.40 |
| Change at Day 2880 (n=27, 26, 27) | -1.47 ± 0.34 | -2.16 ± 0.61 | -2.25 ± 0.49 |
| Change at Day 3060 (n=14, 10, 8) | -1.06 ± 0.36 | -2.10 ± 1.00 | -1.73 ± 0.50 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 50.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 66, 64) | 30.90 ± 8.14 | 31.03 ± 8.87 | 32.57 ± 7.94 |
| Baseline for Day 720 cohort (n=73, 55, 53) | 31.44 ± 8.35 | 30.83 ± 8.03 | 32.48 ± 7.14 |
| Baseline for Day 1080 cohort (n=63, 50, 49) | 31.56 ± 8.14 | 31.73 ± 8.63 | 32.38 ± 7.08 |
| Baseline for Day 1440 cohort (n=59, 46, 44) | 31.46 ± 8.31 | 31.80 ± 8.84 | 32.20 ± 7.44 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 32.19 ± 8.72 | 32.02 ± 8.91 | 32.36 ± 7.57 |
| Baseline for Day 2160 cohort (n=45, 36, 35) | 32.15 ± 8.72 | 32.25 ± 9.07 | 32.29 ± 7.70 |
| Baseline for Day 2520 cohort (n=38, 35, 33) | 31.93 ± 9.50 | 32.75 ± 9.20 | 32.54 ± 7.39 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 32.63 ± 8.71 | 33.65 ± 8.66 | 32.66 ± 7.81 |
| Baseline for Day 3060 cohort (n=17, 17, 16) | 36.81 ± 7.68 | 33.88 ± 9.12 | 33.40 ± 9.52 |
The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 49.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL on Day 360 (n=84, 66, 64) | 9.66 ± 1.05 | 7.13 ± 0.99 | 4.53 ± 1.04 |
| Change from BL on Day 720 (n=73, 55, 53) | 9.15 ± 1.17 | 8.48 ± 1.25 | 8.30 ± 1.10 |
| Change from BL on Day 1080 (n=63, 50, 49) | 9.28 ± 1.22 | 8.14 ± 1.36 | 9.28 ± 1.29 |
| Change from BL on Day 1440 (n=59, 46, 44) | 8.18 ± 1.33 | 9.53 ± 1.28 | 9.50 ± 1.29 |
| Change from BL on Day 1800 (n=54, 43, 42) | 9.30 ± 1.49 | 7.60 ± 1.25 | 9.18 ± 1.20 |
| Change from BL on Day 2160 (n=45, 36, 35) | 9.51 ± 1.72 | 10.61 ± 1.44 | 8.86 ± 1.65 |
| Change from BL on Day 2520 (n=38, 35, 33) | 10.12 ± 1.88 | 8.26 ± 1.58 | 7.92 ± 1.80 |
| Change from BL on Day 2880 (n=33, 30, 31) | 10.97 ± 1.96 | 7.51 ± 1.35 | 9.19 ± 1.64 |
| Change from BL on Day 3060 (n=17, 17, 16) | 8.55 ± 2.74 | 5.70 ± 1.98 | 9.06 ± 2.35 |
SF-36=PCS, MCS, \& 8 individual indices. MCS addresses 4 of the 8 indices: vitality, social functioning, role-emotional, \& mental health. Subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched baseline (Day 0) values \& post-baseline (BL) values are presented for each post-BL visit \& represent only that cohort with measurements available at that post-BL assessment. See Outcome Measure 51 for Change from BL.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline (Day 0) for Day 360 cohort (n=84, 66, 64) | 46.27 ± 12.13 | 42.10 ± 13.08 | 44.44 ± 12.36 |
| Baseline (Day 0) for Day 720 cohort (n=73,55, 53) | 46.17 ± 12.24 | 41.82 ± 13.10 | 44.74 ± 12.62 |
| Baseline for Day 1080 cohort (n=63, 50, 49) | 45.45 ± 11.76 | 42.10 ± 12.82 | 44.53 ± 12.52 |
| Baseline for Day 1440 cohort (n=59, 46, 44) | 45.32 ± 11.38 | 42.48 ± 13.06 | 44.66 ± 12.74 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 45.07 ± 11.31 | 41.87 ± 12.99 | 44.68 ± 12.85 |
| Baseline for Day 2160 cohort (n=45, 36, 35) | 45.57 ± 11.45 | 42.09 ± 12.96 | 43.89 ± 12.36 |
| Baseline for Day 2520 cohort (n=38, 35, 33) | 46.35 ± 12.07 | 42.53 ± 13.34 | 44.51 ± 12.09 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 45.48 ± 11.45 | 40.74 ± 12.02 | 43.51 ± 11.20 |
| Baseline for Day 3060 cohort (n=17, 17, 16) | 46.24 ± 13.26 | 40.94 ± 13.47 | 45.14 ± 12.42 |
The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 51.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 66, 64) | 6.05 ± 1.19 | 6.03 ± 1.32 | 2.53 ± 1.34 |
| Change from BL at Day 720 (n=73,55, 53) | 4.59 ± 1.29 | 6.02 ± 1.49 | 4.17 ± 1.57 |
| Change from BL at Day 1080 (n=63, 50, 49) | 4.01 ± 1.23 | 4.87 ± 1.44 | 5.52 ± 1.78 |
| Change from BL at Day 1440 (n=59, 46, 44) | 4.67 ± 1.31 | 6.68 ± 1.34 | 4.76 ± 2.12 |
| Change from BL at Day 1800 (n=54, 43, 42) | 5.32 ± 1.38 | 4.59 ± 1.66 | 2.26 ± 1.71 |
| Change from BL at Day 2160 (n=45, 36, 35) | 6.22 ± 1.47 | 5.95 ± 1.46 | 4.55 ± 2.19 |
| Change from BL at Day 2520 (n=38, 35, 33) | 2.81 ± 1.85 | 7.34 ± 1.75 | 4.44 ± 2.26 |
| Change from BL at Day 2880 (n=33, 30, 31) | 5.00 ± 1.92 | 6.97 ± 1.69 | 3.87 ± 2.18 |
| Change from BL at Day 3060 (n=17, 17, 16) | 4.81 ± 2.90 | 5.51 ± 2.88 | 1.91 ± 3.26 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 54.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 67, 66) | 29.84 ± 9.57 | 30.18 ± 10.23 | 30.80 ± 9.48 |
| Baseline for Day 720 cohort (n=73, 56, 53) | 30.39 ± 9.63 | 30.58 ± 9.99 | 30.79 ± 9.10 |
| Baseline for Day 1080 cohort (n=64, 50, 49) | 30.27 ± 9.38 | 31.21 ± 10.35 | 30.95 ± 8.95 |
| Baseline for Day 1440 cohort (n=60, 46, 44) | 30.47 ± 9.43 | 31.50 ± 10.12 | 31.26 ± 9.15 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 30.96 ± 9.74 | 31.81 ± 10.45 | 31.48 ± 9.08 |
| Baseline for Day 2160 cohort (n=45, 37, 35) | 31.41 ± 10.16 | 32.24 ± 10.42 | 31.56 ± 9.51 |
| Baseline for Day 2520 cohort (n=38, 35, 33) | 31.47 ± 10.64 | 32.79 ± 10.26 | 32.04 ± 8.95 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 31.77 ± 10.62 | 33.56 ± 10.07 | 32.18 ± 9.32 |
| Baseline for Day 3060 cohort (n=18, 18, 16) | 34.97 ± 9.74 | 33.92 ± 9.55 | 32.37 ± 10.37 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 53.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 67, 66) | 8.58 ± 1.11 | 6.53 ± 0.99 | 3.31 ± 0.92 |
| Change from BL at Day 720 (n=73, 56, 53) | 8.36 ± 1.16 | 7.50 ± 1.32 | 7.30 ± 1.15 |
| Change from BL at Day 1080 (n=64, 50, 49) | 8.36 ± 1.32 | 6.22 ± 1.49 | 7.62 ± 1.08 |
| Change from BL at Day 1440 (n=60, 46, 44) | 7.91 ± 1.48 | 7.19 ± 1.48 | 7.58 ± 1.22 |
| Change from BL at Day 1800 (n=54, 43, 42) | 8.39 ± 1.60 | 5.48 ± 1.45 | 6.16 ± 1.33 |
| Change from BL at Day 2160 (n=45, 37, 35) | 9.24 ± 1.74 | 8.28 ± 1.53 | 5.46 ± 1.32 |
| Change from BL at Day 2520 (n=38, 35, 33) | 7.92 ± 2.02 | 6.58 ± 1.74 | 5.87 ± 1.64 |
| Change from BL at Day 2880 (n=33, 30, 31) | 9.93 ± 2.09 | 5.90 ± 1.63 | 6.63 ± 1.49 |
| Change from BL at Day 3060 (n=18, 18, 16) | 6.21 ± 2.87 | 4.29 ± 1.91 | 6.16 ± 2.01 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 56.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 66, 66) | 33.68 ± 9.66 | 31.70 ± 7.77 | 34.17 ± 8.82 |
| Baseline for Day 720 cohort (n=73, 56, 53) | 34.06 ± 10.09 | 31.49 ± 7.51 | 33.69 ± 8.78 |
| Baseline for Day 1080 cohort (n=64, 50, 49) | 34.36 ± 10.22 | 32.20 ± 7.96 | 33.58 ± 8.42 |
| Baseline for Day 1440 cohort (n=60, 46, 44) | 33.97 ± 9.90 | 32.57 ± 8.20 | 33.10 ± 7.98 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 33.85 ± 9.79 | 32.39 ± 8.31 | 33.01 ± 8.01 |
| Baseline for Day 2160 cohort (n=45, 36, 35) | 33.61 ± 9.61 | 33.26 ± 8.85 | 32.80 ± 7.63 |
| Baseline for Day 2520 cohort (n=38, 35, 33) | 33.72 ± 9.85 | 33.41 ± 8.93 | 33.95 ± 8.68 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 33.74 ± 9.60 | 33.38 ± 8.45 | 33.43 ± 7.90 |
| Baseline for Day 3060 cohort (n=17, 18, 16) | 37.52 ± 11.71 | 34.63 ± 8.57 | 35.47 ± 9.82 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 55.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 66, 66) | 10.10 ± 1.32 | 6.97 ± 1.22 | 5.68 ± 1.51 |
| Change from BL at Day 720 (n=73, 56, 53) | 9.69 ± 1.51 | 9.60 ± 1.49 | 9.03 ± 1.55 |
| Change from BL at Day 1080 (n=64, 50, 49) | 8.73 ± 1.63 | 8.06 ± 1.69 | 12.12 ± 1.86 |
| Change from BL at Day 1440 (n=60, 46, 44) | 7.78 ± 1.69 | 10.30 ± 1.66 | 11.89 ± 1.76 |
| Change from BL at Day 1800 (n=54, 43, 42) | 9.95 ± 1.85 | 7.57 ± 1.50 | 11.11 ± 1.74 |
| Change from BL at Day 2160 (n=45, 36, 35) | 10.37 ± 1.86 | 10.41 ± 1.92 | 11.65 ± 2.14 |
| Change from BL at Day 2520 (n=38, 35, 33) | 9.49 ± 2.20 | 9.50 ± 1.94 | 9.43 ± 2.57 |
| Change from BL at Day 2880 (n=33, 30, 31) | 11.79 ± 2.32 | 7.31 ± 1.84 | 10.95 ± 2.32 |
| Change from BL at Day 3060 (n=17, 18, 16) | 11.65 ± 3.53 | 4.32 ± 2.63 | 10.61 ± 3.48 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 58.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 67, 66) | 35.91 ± 8.52 | 33.82 ± 7.69 | 36.39 ± 7.98 |
| Baseline for Day 720 cohort (n=73, 56, 53) | 36.10 ± 8.76 | 34.23 ± 7.63 | 35.93 ± 7.35 |
| Baselinefor Day 1080 cohort (n=64, 50, 49) | 36.06 ± 8.73 | 34.57 ± 7.84 | 36.04 ± 7.48 |
| Baseline for Day 1440 cohort (n=60, 46, 44) | 35.28 ± 8.59 | 34.56 ± 7.99 | 35.42 ± 7.37 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 36.22 ± 8.94 | 34.57 ± 8.23 | 35.54 ± 7.27 |
| Baseline for Day 2160 cohort (n=45, 36, 35) | 35.57 ± 9.35 | 34.50 ± 8.27 | 35.59 ± 7.65 |
| Baseline for Day 2520 cohort (n=38, 35, 33) | 35.35 ± 9.49 | 35.29 ± 8.32 | 35.32 ± 7.73 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 35.12 ± 9.68 | 35.76 ± 8.27 | 35.29 ± 8.03 |
| Baseline for Day 3060 cohort (n=17, 18, 16) | 38.83 ± 9.60 | 35.75 ± 7.82 | 37.72 ± 8.69 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 57.
| Units on a Scale | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 67, 66) | 10.35 ± 1.14 | 9.26 ± 1.07 | 4.12 ± 1.13 |
| Change from BL at Day 720 (n=73, 56, 53) | 8.84 ± 1.36 | 9.40 ± 1.33 | 9.17 ± 1.42 |
| Change from BL at Day 1,080 (n=64, 50, 49) | 9.02 ± 1.35 | 9.67 ± 1.55 | 9.48 ± 1.59 |
| Change from BL at Day 1,440 (n=60, 46, 44) | 9.54 ± 1.37 | 11.38 ± 1.59 | 10.86 ± 1.61 |
| Change from BL at Day 1,800 (n=54, 43, 42) | 9.08 ± 1.50 | 8.73 ± 1.62 | 10.03 ± 1.64 |
| Change from BL at Day 2,160 (n=45, 36, 35) | 10.27 ± 1.83 | 12.11 ± 1.66 | 10.83 ± 1.74 |
| Change from BL at Day 2,520 (n=38, 35, 33) | 10.97 ± 1.90 | 10.55 ± 1.61 | 10.11 ± 1.76 |
| Change from BL at Day 2,880 (n=33, 30, 31) | 11.68 ± 1.99 | 10.08 ± 1.66 | 10.86 ± 1.86 |
| Change from BL at Day 3,060 (n=17, 18, 16) | 9.28 ± 3.77 | 6.45 ± 2.85 | 10.52 ± 3.15 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 60.
| Units on a Scale | OL Abatacept: Original 10 mg / kg Group | OL Abatacept: Original 2 mg / kg Group | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| BL (Day 0) for Day 360 cohort (n=84, 67, 66) | 37.11 ± 9.23 | 35.87 ± 9.23 | 37.45 ± 9.01 |
| BL (Day 0) for Day 720 cohort (n=73, 56, 53) | 37.36 ± 9.30 | 35.61 ± 8.96 | 38.06 ± 8.26 |
| BL (Day 0) for Day 1,080 cohort (n=64, 50, 49) | 37.55 ± 9.38 | 35.78 ± 9.13 | 37.45 ± 8.37 |
| BL (Day 0) for Day 1,440 cohort (n=60, 46, 44) | 37.41 ± 9.12 | 35.67 ± 8.88 | 37.64 ± 8.60 |
| BL (Day 0) for Day 1,800 cohort (n=54, 43, 42) | 38.08 ± 9.75 | 35.60 ± 8.98 | 37.78 ± 8.59 |
| BL (Day 0) for Day 2,160 cohort (n=45, 37, 35) | 38.81 ± 9.94 | 35.69 ± 8.85 | 36.93 ± 8.65 |
| BL (Day 0) for Day 2,520 cohort (n=38, 36, 33) | 39.25 ± 10.40 | 36.17 ± 9.40 | 36.98 ± 8.50 |
| BL (Day 0) for Day 2,880 cohort (n=33, 30, 31) | 40.09 ± 10.49 | 35.39 ± 8.54 | 36.57 ± 8.54 |
| BL (Day 0) for Day 3,060 cohort (n=18, 18, 16) | 41.37 ± 11.49 | 33.88 ± 8.58 | 36.84 ± 9.18 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 59.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 67, 66) | 6.98 ± 0.90 | 6.08 ± 1.05 | 3.48 ± 0.71 |
| Change from BL at Day 720 (n=73, 56, 53) | 5.96 ± 1.06 | 5.99 ± 1.24 | 5.09 ± 0.96 |
| Change from BL at Day 1080 (n=64, 50, 49) | 6.18 ± 1.12 | 6.27 ± 1.07 | 5.63 ± 1.05 |
| Change from BL at Day 1440 (n=60, 46, 44) | 5.84 ± 1.12 | 8.01 ± 0.91 | 4.80 ± 1.17 |
| Change from BL at Day 1800 (n=54, 43, 42) | 6.52 ± 1.25 | 6.87 ± 1.26 | 3.97 ± 1.25 |
| Change from BL at Day 2160 (n=45, 37, 35) | 5.27 ± 1.40 | 8.73 ± 1.30 | 5.38 ± 1.56 |
| Change from BL at Day 2520 (n=38, 36, 33) | 6.42 ± 1.85 | 6.51 ± 1.21 | 5.38 ± 1.43 |
| Change from BL at Day 2880 (n=33, 30, 31) | 6.37 ± 2.05 | 8.67 ± 1.45 | 5.61 ± 1.30 |
| Change from BL at Day 3060 (n=18, 18, 16) | 5.09 ± 2.73 | 6.82 ± 2.21 | 3.88 ± 1.46 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 62.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 67, 66) | 41.17 ± 8.29 | 40.68 ± 8.84 | 42.49 ± 9.81 |
| Baseline for Day 720 cohort (n=73, 55, 53) | 41.15 ± 8.29 | 41.22 ± 8.25 | 43.25 ± 9.84 |
| Baseline for Day 1080 cohort (n=63, 50, 49) | 40.65 ± 8.24 | 41.72 ± 8.56 | 42.58 ± 9.81 |
| Baseline for Day 1440 cohort (n=59, 46, 44) | 40.84 ± 8.17 | 41.85 ± 8.81 | 43.08 ± 9.81 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 41.09 ± 8.27 | 41.40 ± 8.72 | 43.42 ± 9.83 |
| Baseline for Day 2160 cohort (n=45, 37, 35) | 41.66 ± 8.59 | 40.93 ± 8.65 | 42.77 ± 10.04 |
| Baseline for Day 2520 cohort (n=38, 36, 33) | 41.66 ± 9.03 | 41.43 ± 9.26 | 42.74 ± 9.64 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 42.12 ± 8.80 | 40.22 ± 8.22 | 42.34 ± 9.57 |
| Baseline for Day 3060 cohort (n=18, 17, 16) | 44.06 ± 8.66 | 41.12 ± 7.29 | 42.40 ± 9.20 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 61.
| Units on a Scale | OL Abatacept: Original 10 mg /kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 67, 66) | 8.50 ± 1.02 | 4.91 ± 1.03 | 1.86 ± 1.04 |
| Change from BL at Day 720 (n=73, 55, 53) | 7.77 ± 1.01 | 6.20 ± 1.27 | 4.69 ± 1.20 |
| Change from BL at Day 1080 (n=63, 50, 49) | 7.73 ± 1.18 | 6.30 ± 1.16 | 6.46 ± 1.23 |
| Change from BL at Day 1440 (n=59, 46, 44) | 6.00 ± 1.25 | 7.61 ± 1.23 | 4.73 ± 1.62 |
| Change from BL at Day 1800 (n=54, 43, 42) | 7.44 ± 1.41 | 6.33 ± 1.14 | 3.49 ± 1.70 |
| Change from BL at Day 2160 (n=45, 37, 35) | 8.15 ± 1.53 | 7.10 ± 1.18 | 4.60 ± 1.96 |
| Change from BL at Day 2520 (n=38, 36, 33) | 6.64 ± 1.98 | 6.86 ± 1.21 | 3.82 ± 2.03 |
| Change from BL at Day 2880 (n=33, 30, 31) | 6.65 ± 1.86 | 7.10 ± 1.34 | 4.76 ± 1.70 |
| Change from BL at Day 3060 (n=18, 17, 16) | 4.60 ± 3.02 | 6.68 ± 2.21 | 3.99 ± 2.34 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 64.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo Group |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 67, 66) | 38.59 ± 10.99 | 34.45 ± 10.52 | 38.14 ± 10.91 |
| Baseline for Day 720 cohort (n=73, 56, 53) | 39.37 ± 11.13 | 35.04 ± 9.81 | 39.11 ± 10.74 |
| Baseline for Day 1080 cohort (n=64, 50, 49) | 38.99 ± 11.04 | 34.77 ± 9.22 | 39.08 ± 10.71 |
| Baseline for Day 1440 cohort (n=60, 46, 44) | 38.77 ± 11.04 | 35.19 ± 9.36 | 38.88 ± 11.05 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 38.84 ± 11.52 | 34.92 ± 9.54 | 39.04 ± 11.03 |
| Baseline for Day 2160 cohort (n=45, 36, 35) | 39.16 ± 11.45 | 35.42 ± 9.54 | 38.06 ± 10.97 |
| Baseline for Day 2520 cohort (n=38, 35, 33) | 39.42 ± 11.82 | 35.11 ± 9.85 | 38.88 ± 10.93 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 39.54 ± 12.14 | 36.33 ± 8.80 | 38.40 ± 10.75 |
| Baseline for Day 3060 cohort (n=17, 18, 16) | 42.77 ± 11.66 | 36.33 ± 8.78 | 38.82 ± 12.52 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 63.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 67, 66) | 8.47 ± 1.25 | 8.02 ± 1.11 | 4.44 ± 1.12 |
| Change from BL at Day 720 (n=73, 56, 53) | 6.62 ± 1.39 | 8.43 ± 1.35 | 6.86 ± 1.28 |
| Change from BL at Day 1080 (n=64, 50, 49) | 5.94 ± 1.20 | 8.25 ± 1.05 | 7.87 ± 1.38 |
| Change from BL at Day 1440 (n=60, 46, 44) | 6.24 ± 1.51 | 9.56 ± 1.39 | 8.02 ± 1.82 |
| Change from BL at Day 1800 (n=54, 43, 42) | 8.65 ± 1.49 | 6.69 ± 1.56 | 6.59 ± 1.86 |
| Change from BL at Day 2160 (n=45, 36, 35) | 9.53 ± 1.58 | 9.95 ± 1.29 | 7.13 ± 2.08 |
| Change from BL at Day 2520 (n=38, 35, 33) | 5.00 ± 2.24 | 10.70 ± 1.40 | 5.76 ± 2.19 |
| Change from BL at Day 2880 (n=33, 30, 31) | 7.90 ± 1.99 | 6.69 ± 1.70 | 5.25 ± 1.93 |
| Change from BL at Day 3060 (n=17, 18, 16) | 6.07 ± 2.98 | 6.03 ± 2.23 | 4.07 ± 3.03 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 66.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 67, 64) | 40.29 ± 14.09 | 36.63 ± 14.30 | 38.88 ± 14.28 |
| Baseline for Day 720 cohort (n=73, 56, 53) | 40.19 ± 14.04 | 36.15 ± 14.08 | 38.84 ± 14.68 |
| Baseline for Day 1080 cohort (n=64, 50, 49) | 39.21 ± 13.92 | 37.01 ± 14.09 | 39.43 ± 14.76 |
| Baseline for Day 1440 cohort (n=60, 46, 44) | 38.84 ± 13.90 | 37.48 ± 14.02 | 39.30 ± 14.81 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 38.76 ± 13.97 | 36.97 ± 14.19 | 39.29 ± 14.76 |
| Baseline for Day 2160 cohort (n=45, 36, 35) | 38.72 ± 14.29 | 37.78 ± 14.02 | 39.09 ± 14.97 |
| Baseline for Day 2520 cohort (n=38, 35, 33) | 39.54 ± 14.85 | 37.88 ± 14.21 | 40.34 ± 14.67 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 38.10 ± 14.62 | 36.73 ± 14.29 | 39.37 ± 14.62 |
| Baseline for Day 3060 cohort (n=17, 18, 16) | 40.47 ± 14.93 | 37.78 ± 14.45 | 44.15 ± 14.12 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 65.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 67, 64) | 8.03 ± 1.58 | 7.55 ± 2.05 | 3.79 ± 1.94 |
| Change from BL at Day 720 (n=73, 56, 53) | 6.93 ± 1.68 | 8.28 ± 2.29 | 6.36 ± 1.97 |
| Change from BL at Day 1080 (n=64, 50, 49) | 5.76 ± 1.88 | 4.64 ± 2.24 | 7.95 ± 2.27 |
| Change from BL at Day 1440 (n=60, 46, 44) | 6.67 ± 1.86 | 8.24 ± 2.31 | 7.18 ± 2.56 |
| Change from BL at Day 1800 (n=54, 43, 42) | 7.41 ± 2.04 | 4.16 ± 2.48 | 4.51 ± 2.19 |
| Change from BL at Day 2160 (n=45, 36, 35) | 7.84 ± 2.16 | 7.61 ± 2.40 | 6.47 ± 2.87 |
| Change from BL at Day 2520 (n=38, 35, 33) | 5.82 ± 2.34 | 8.43 ± 2.92 | 5.75 ± 2.64 |
| Change from BL at Day 2880 (n=33, 30, 31) | 8.94 ± 2.72 | 8.78 ± 2.32 | 4.76 ± 3.04 |
| Change from BL at Day 3060 (n=17, 18, 16) | 9.92 ± 4.09 | 5.85 ± 3.92 | 0.66 ± 4.66 |
SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 68.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Baseline for Day 360 cohort (n=84, 67, 66) | 44.66 ± 11.94 | 41.29 ± 12.28 | 42.35 ± 11.62 |
| Baseline for Day 720 cohort (n=73, 55, 53) | 44.53 ± 12.19 | 40.49 ± 12.72 | 41.99 ± 11.58 |
| Baseline for Day 1080 cohort (n=63, 50, 49) | 44.13 ± 11.82 | 40.81 ± 12.66 | 41.44 ± 11.55 |
| Baseline for Day 1440 cohort (n=59, 46, 44) | 44.24 ± 11.09 | 41.11 ± 12.61 | 41.60 ± 11.77 |
| Baseline for Day 1800 cohort (n=54, 43, 42) | 44.13 ± 11.14 | 40.78 ± 12.39 | 41.50 ± 11.78 |
| Baseline for Day 2160 cohort (n=45, 37, 35) | 44.79 ± 11.18 | 40.50 ± 12.17 | 40.89 ± 11.05 |
| Baselinefor Day 2520 cohort (n=38, 36, 33) | 45.54 ± 11.10 | 42.05 ± 12.54 | 41.06 ± 11.44 |
| Baseline for Day 2880 cohort (n=33, 30, 31) | 44.87 ± 9.92 | 39.77 ± 10.76 | 40.24 ± 10.92 |
| Baseline for Day 3060 cohort (n=18, 17, 16) | 44.89 ± 11.85 | 39.49 ± 11.62 | 40.18 ± 12.07 |
SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 67.
| Units on a Scale | OL Abatacept: Original 10 mg/kg | OL Abatacept: Original 2 mg/kg | OL Abatacept: Original Placebo |
|---|---|---|---|
| Change from BL at Day 360 (n=84, 67, 66) | 5.41 ± 1.10 | 5.74 ± 1.14 | 2.60 ± 1.13 |
| Change from BL at Day 720 (n=73, 55, 53) | 4.22 ± 1.18 | 5.49 ± 1.29 | 4.59 ± 1.50 |
| Change from BL at Day 1080 (n=63, 50, 49) | 4.62 ± 1.03 | 5.41 ± 1.48 | 5.54 ± 1.59 |
| Change from BL at Day 1440 (n=59, 46, 44) | 4.81 ± 1.14 | 5.96 ± 1.24 | 5.59 ± 1.93 |
| Change from BL at Day 1800 (n=54, 43, 42) | 4.47 ± 1.34 | 5.44 ± 1.45 | 3.15 ± 1.80 |
| Change from BL at Day 2160 (n=45, 37, 35) | 5.82 ± 1.33 | 5.96 ± 1.26 | 5.29 ± 1.94 |
| Change from BL at Day 2520 (n=38, 36, 33) | 3.15 ± 1.92 | 6.06 ± 1.50 | 6.33 ± 1.94 |
| Change from BL at Day 2880 (n=33, 30, 31) | 4.96 ± 1.71 | 6.30 ± 1.60 | 6.78 ± 1.98 |
| Change from BL at Day 3060 (n=18, 17, 16) | 2.65 ± 2.35 | 4.68 ± 2.59 | 6.99 ± 2.68 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aba 10mg/kg+MTX | — | 17/115 (14.8%) | 96/115 (83.5%) |
| Aba 2mg/kg+MTX | — | 19/105 (18.1%) | 98/105 (93.3%) |
| Abatacept (LT) | — | 117/219 (53.4%) | 200/219 (91.3%) |
| Placebo+MTX | — | 21/119 (17.6%) | 108/119 (90.8%) |
| Event | Aba 10mg/kg+MTX | Aba 2mg/kg+MTX | Abatacept (LT) | Placebo+MTX |
|---|---|---|---|---|
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 0/115 | 1/105 | 18/219 | 2/119 |
| CHEST PAINGeneral disorders | 1/115 | 4/105 | 2/219 | 0/119 |
| PNEUMONIAInfections and infestations | 0/115 | 0/105 | 8/219 | 1/119 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/115 | 0/105 | 7/219 | 0/119 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/115 | 0/105 | 6/219 | 0/119 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/115 | 0/105 | 5/219 | 0/119 |
| DEEP VEIN THROMBOSISVascular disorders | 0/115 | 0/105 | 4/219 | 0/119 |
| CHOLELITHIASISHepatobiliary disorders | 1/115 | 0/105 | 4/219 | 0/119 |
| HIP FRACTUREInjury, poisoning and procedural complications | 0/115 | 0/105 | 4/219 | 1/119 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/115 | 0/105 | 4/219 | 0/119 |
| Event | Aba 10mg/kg+MTX | Aba 2mg/kg+MTX | Abatacept (LT) | Placebo+MTX |
|---|---|---|---|---|
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 35/115 | 50/105 | 100/219 | 55/119 |
| NASOPHARYNGITISInfections and infestations | 17/115 | 19/105 | 76/219 | 11/119 |
| BACK PAINMusculoskeletal and connective tissue disorders | 10/115 | 9/105 | 65/219 | 9/119 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 13/115 | 10/105 | 58/219 | 9/119 |
| COUGHRespiratory, thoracic and mediastinal disorders | 16/115 | 10/105 | 52/219 | 15/119 |
| BRONCHITISInfections and infestations | 9/115 | 7/105 | 51/219 | 5/119 |
| SINUSITISInfections and infestations | 5/115 | 7/105 | 50/219 | 10/119 |
| URINARY TRACT INFECTIONInfections and infestations | 3/115 | 2/105 | 48/219 | 3/119 |
| HYPERTENSIONVascular disorders | 8/115 | 12/105 | 45/219 | 9/119 |
| HEADACHENervous system disorders | 16/115 | 17/105 | 43/219 | 19/119 |
| Age Continuous(years) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Mean | 55.8 ± 12.5 | 54.4 ± 11.3 | 54.7 ± 12.0 | 55.0 ± 11.9 |
| Sex: Female, Male(Participants) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Female | 86 | 66 | 79 | 231 |
| Male | 29 | 39 | 40 | 108 |
| Race/Ethnicity, Customized(Participants) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| White | 100 | 91 | 104 | 295 |
| Black | 6 | 0 | 3 | 9 |
| Other | 9 | 14 | 12 | 35 |
| Weight(Kg) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Mean | 77.8 ± 18.6 | 78.7 ± 21.4 | 79.9 ± 17.6 | 78.8 ± 19.2 |
| Rheumatoid Factor Status(Participants) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Negative | 14 | 15 | 27 | 56 |
| Positive | 99 | 90 | 90 | 279 |
| Number of Tender Joints(Joints) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Mean | 30.8 ± 12.2 | 28.2 ± 12.0 | 29.2 ± 13.0 | 29.4 ± 12.4 |
| Number of Swollen Joints(Joints) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Mean | 21.3 ± 8.4 | 20.2 ± 8.9 | 21.8 ± 8.8 | 21.1 ± 8.7 |
| C-Reactive Protein (CRP) Serum Level(mg/dL) | Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) | Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate | Double-Blind (DB) Placebo + Methotrexate | Total |
|---|---|---|---|---|
| Mean | 2.9 ± 2.8 | 3.2 ± 2.5 | 3.2 ± 3.2 | 3.1 ± 2.9 |
1 further baseline measures are reported on the registry.
The record gives a start of Oct 2000, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept